Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Omicron BA.4/5-Delta Recombinant Protein Vaccine in Adults
NCT06025812Unknown
- Sponsor
- Zhifei Biological
- Start
- Sep 2023
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Randomised, double-blind trial of Omicron BA.4/5-Delta recombinant protein vaccine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Zhifei Biological. Primary endpoints: Number of adverse events, Laboratory markers of immunity and 1 more. Status: unknown.
02
Drugs
Omicron BA.4/5-Delta recombinant protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06025812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025812.